No "Japan pharma for sale signs," by P Reed Maurer
Want to acquire a Japanese pharmaceutical company? Join the back of a long line of companies with the same objective. There is no shortage of willing buyers, but trying to find a willing seller is like looking for a needle in a haystack, says P Reed Maurer, long-time Japanese pharma industry watcher and president of International Alliances Limited (IAL) in an exclusive article for The Pharma Letter.
The situation is succinctly described by the following quotation: “The only investment barrier to Japan for Western pharmaceutical companies since 1975 is their inability to make attractive acquisitions,” he notes.
Below is the chronology of “Out/In” deals since the first two in 1983. This does not include
foreign company buy-outs of joint ventures. Please note:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze